Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Analyst Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRDN Stock 12 Month Forecast
Average Price Target
$39.73
▲(103.12% Upside)
| Highest Price Target$61.00 | Average Price Target$39.73 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$46
Buy
135.17%
Upside
Reiterated
09/20/25
Viridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline OutlookWeekly Recap - 09/20/25 From: , Saturday, September 20, 2025 4:01 PM Sam Slutsky | | As a follow-up to the recent Phase 3 BOND-003 data with CG Oncology’s (Nasdaq: CGON) cretostimogene (targeted oncolytic virus) in BCG unresponsive HR NMIBC (LINK to our note), we lay out the NMIBC landscape more broadly below, and where cretostimogene is currently being developed.As a reminder, cretostimogene demonstrated a 75.5% (n=83/110) anytime complete response rate (CRR), a 46.4% (n=51/110) 12-month 24-month CRR (46/110) among evaluable BCG-unresponsive HR NMIBC patients. Importantly, the treatment was tolerable with no Grade ≥3 treatment related adverse events (TRAEs) and no treatment related discontinuations.
Leerink Partners
―
Buy
―
Reiterated
09/16/25
BTIG
$61
Buy
211.86%
Upside
Reiterated
09/15/25
Promising Developments and Strategic Advancements Justify Buy Rating for Viridian TherapeuticsWe also expect payors to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option. If positive, REVEAL-1/2 are expected to support a BLA submission in YE26. The BLA submission for veligrotug is now expected in November 2025 (previously guided to 2H25). Veligrotug has received Breakthrough Therapy Designation, which could support Priority Review, so we could see a commercial launch of veligrotug as early as mid-2026 if Priority Review is granted. VRDN has also strengthened its IP portfolio with the addition of a composition patent for VRDN-003 with term to 2041 and a methods patent for veligrotug with term to 2042.
Wedbush
$40
Buy
104.50%
Upside
Reiterated
09/15/25
Needham
$34
Buy
73.82%
Upside
Reiterated
09/15/25
Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial PositionWe believe VRDN- 003's SC-administration via a low-volume autoinjector offers game-changing potential for TED, and the readouts of the REVEAL trials could significantly enhance the co's valuation and appeal as an M&A target.
Jefferies
$44
Buy
124.95%
Upside
Initiated
08/24/25
Evercore ISI
$38
Buy
94.27%
Upside
Reiterated
08/11/25
H.C. Wainwright
$34
Buy
73.82%
Upside
Reiterated
08/07/25
Oppenheimer
$28→$32
Buy
63.60%
Upside
Reiterated
08/07/25
RBC Capital
$45→$41
Buy
109.61%
Upside
Reiterated
08/07/25
Wells Fargo
$26
Hold
32.92%
Upside
Reiterated
08/06/25
TD Cowen
―
Buy
―
Reiterated
08/06/25
B. Riley Securities
$19
Hold
-2.86%
Downside
Reiterated
05/21/25
Citizens JMP
$42→$38
Buy
94.27%
Upside
Reiterated
05/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$46
Buy
135.17%
Upside
Reiterated
09/20/25
Viridian Therapeutics: Buy Rating Affirmed on Pivotal Program Completion and Promising Pipeline OutlookWeekly Recap - 09/20/25 From: , Saturday, September 20, 2025 4:01 PM Sam Slutsky | | As a follow-up to the recent Phase 3 BOND-003 data with CG Oncology’s (Nasdaq: CGON) cretostimogene (targeted oncolytic virus) in BCG unresponsive HR NMIBC (LINK to our note), we lay out the NMIBC landscape more broadly below, and where cretostimogene is currently being developed.As a reminder, cretostimogene demonstrated a 75.5% (n=83/110) anytime complete response rate (CRR), a 46.4% (n=51/110) 12-month 24-month CRR (46/110) among evaluable BCG-unresponsive HR NMIBC patients. Importantly, the treatment was tolerable with no Grade ≥3 treatment related adverse events (TRAEs) and no treatment related discontinuations.
Leerink Partners
―
Buy
―
Reiterated
09/16/25
BTIG
$61
Buy
211.86%
Upside
Reiterated
09/15/25
Promising Developments and Strategic Advancements Justify Buy Rating for Viridian TherapeuticsWe also expect payors to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option. If positive, REVEAL-1/2 are expected to support a BLA submission in YE26. The BLA submission for veligrotug is now expected in November 2025 (previously guided to 2H25). Veligrotug has received Breakthrough Therapy Designation, which could support Priority Review, so we could see a commercial launch of veligrotug as early as mid-2026 if Priority Review is granted. VRDN has also strengthened its IP portfolio with the addition of a composition patent for VRDN-003 with term to 2041 and a methods patent for veligrotug with term to 2042.
Wedbush
$40
Buy
104.50%
Upside
Reiterated
09/15/25
Needham
$34
Buy
73.82%
Upside
Reiterated
09/15/25
Positive Outlook for Viridian Therapeutics: Buy Rating Backed by Promising Trial Developments and Strong Financial PositionWe believe VRDN- 003's SC-administration via a low-volume autoinjector offers game-changing potential for TED, and the readouts of the REVEAL trials could significantly enhance the co's valuation and appeal as an M&A target.
Jefferies
$44
Buy
124.95%
Upside
Initiated
08/24/25
Evercore ISI
$38
Buy
94.27%
Upside
Reiterated
08/11/25
H.C. Wainwright
$34
Buy
73.82%
Upside
Reiterated
08/07/25
Oppenheimer
$28→$32
Buy
63.60%
Upside
Reiterated
08/07/25
RBC Capital
$45→$41
Buy
109.61%
Upside
Reiterated
08/07/25
Wells Fargo
$26
Hold
32.92%
Upside
Reiterated
08/06/25
TD Cowen
―
Buy
―
Reiterated
08/06/25
B. Riley Securities
$19
Hold
-2.86%
Downside
Reiterated
05/21/25
Citizens JMP
$42→$38
Buy
94.27%
Upside
Reiterated
05/07/25
Best Analysts Covering Viridian Therapeutics
1 Month
xxx
Success Rate
15/30 ratings generated profit
Average Return
+3.80%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.80% per trade.
3 Months
xxx
Success Rate
22/42 ratings generated profit
Average Return
+2.66%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +2.66% per trade.
1 Year
Success Rate
22/42 ratings generated profit
Average Return
+1.71%
reiterated a buy rating 10 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +1.71% per trade.
2 Years
xxx
Success Rate
24/42 ratings generated profit
Average Return
+8.16%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +8.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRDN Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
16
16
17
12
16
Buy
4
3
5
3
4
Hold
6
7
12
10
8
Sell
2
2
1
0
0
Strong Sell
0
0
0
0
0
total
28
28
35
25
28
Each month's total comprises the sum of three months' worth of ratings.
VRDN Financial Forecast
VRDN Stock Forecast FAQ
What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 39.73.
What is VRDN’s upside potential, based on the analysts’ average price target?
Viridian Therapeutics has 103.12% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRDN a Buy, Sell or Hold?
Viridian Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
What is Viridian Therapeutics’s price target?
The average price target for Viridian Therapeutics is 39.73. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $26.00. The average price target represents 103.12% Increase from the current price of $19.56.
The highest analyst price target is $61.00 ,the lowest forecast is $26.00. The average price target represents 103.12% Increase from the current price of $19.56.
What do analysts say about Viridian Therapeutics?
Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of VRDN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.